Breast cancer causes great threats to public health worldwide. The aim of this study was to investigate the correlation between Ki-67 expression and the hemodynamics of contrast-enhanced ultrasound (CEUS) in patients with infiltrative ductal carcinoma (IDC). CEUS was performed on 109 masses in 85 IDC cases before resection. Based on the immunohistochemical staining on the antigen Ki-67, the masses were divided into negative group, weakly positive group, positive group, and strong-positive group. Significant statistical differences were noticed in time to peak, arrive intensity, and peak intensity in the positive groups compared with the negative group. Compared with the positive groups, the negative group showed significant statistical differences in arrive intensity and peak intensity. The antigen Ki-67 was positively correlated with arrived intensity, intensity changes, and rising curve's slope. In contrast, it was negatively correlated with arrived time, time to peak, and continuous time. The hemodynamic parameters of CEUS were correlated with the expression of antigen Ki-67. On this basis, Ki-67 is an effective supplement to the diagnosis of IDC.
Get full access to this article
View all access options for this article.
References
1.
ChenY., HanF., CaoL.H.Dose-response relationship in cisplatin-treated breast cancer xenografts monitored with dynamic contrast-enhanced ultrasound.BMC Cancer2015; 15: 136.
2.
Friedrich-RustM., SchneiderG., BohleR.M.Contrastenhanced sonography of adrenal masses: differentiation of adenomas and nonadenomatous lesions.AJR2008; 191: 1852–60.
3.
KneeshawP.J., LowryM., MantonD.Differentiation of benign from malignant breast disease associated with screening detected microcalcifications using dynamic contrast enhanced magnetic resonance imaging.Breast2006; 15: 29–38.
4.
LiuJ., GaoY.H., LiD.D.Comparative study of contrastenhanced ultrasound qualitative and quantitative analysis for identifying benign and malignant breast tumor lumps.Asian Pac J Cancer Prev2014; 15: 8149–53.
5.
SunJ., CheS.L., PiaoJ.J.Mortalin overexpression predicts poor prognosis in early stage of non-small cell lung cancer.Tumour Biol2017; 39: 1010428317695918.
6.
MatsuzawaF., EinamaT., AbeH.Accurate diagnosis of axillary lymph node metastasis using contrast-enhanced ultrasonography with sonazoid.Mol Clin Oncol2015; 3: 299–302.
7.
WangZ., ZhouQ., LiuJ.Tumor size of breast invasive ductal cancer measured with contrast-enhanced ultrasound predicts regional lymph node metastasis and N stage.Int J Clin Exp Pathol2014; 7: 6985–91.
8.
GuthA.A., Chun KimJ., SchwartzS.The relationship of race, oncotype DX, and Ki67 in a population highly screened for breast cancer.Breast J2017; 23: 177–81.
9.
IwamotoT., KatagiriT., NiikuraN.Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers.Oncotarget2017; 8: 26122–8.
10.
ThomasL.N., ChedraweE.R., BarnesP.J.Prolactin/ androgen-inducible carboxypeptidase-D increases with nitrotyrosine and Ki67 for breast cancer progression in vivo, and upregulates progression markers VEGF-C and Runx2 in vitro.Breast Canc Res Treat2017; 164: 27–40.
11.
JiaW.R., ChaiW.M., TangL.Three-dimensional contrast enhanced ultrasound score and dynamic contrast-enhanced magnetic resonance imaging score in evaluating breast tumor angiogenesis: correlation with biological factors.Eur J Radiol2014; 83: 1098–105.
12.
WeiX., LiY., ZhangS.Evaluation of thyroid cancer in Chinese females with breast cancer by vascular endothelial growth factor (VEGF), microvessel density, and contrast-enhanced ultrasound (CEUS).Tumour Biol2014; 35: 6521–9.
13.
CaoX.L., BaoW., ZhuS.G.Contrast-enhanced ultrasound characteristics of breast cancer: correlation with prognostic factors.Ultrasound Med Biol2014; 40: 11–7.
14.
FeiF., ZhangD., YangZ.The number of polyploid giant cancer cells and epithelial-mesenchymal transition-related proteins are associated with invasion and metastasis in human breast cancer.J Exp Clin Cancer Res2015; 34: 158.
15.
FujiiT., YajimaR., TatsukiH.Significance of lymphatic invasion combined with size of primary tumor for predicting sentinel lymph node metastasis in patients with breast cancer.Anticancer Res2015; 35: 3581–4.
16.
van AstenJ.J., VettukattilR., BuckleT.Increased levels of choline metabolites are an early marker of docetaxel treatment response in BRCA1-mutated mouse mammary tumors: an assessment by ex vivo proton magnetic resonance spectroscopy.J Transl Med2015; 13: 114.
17.
SuetaA., YamamotoY., HayashiM.Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes?Surgery2014; 155: 927–35.
18.
NishimiyaH., KosakaY., YamashitaK.Prognostic significance of Ki-67 in chemotherapy-naive breast cancer patients with 10-year follow-up.Anticancer Res2014; 34: 259–68.
19.
DedeD.S., GumuskayaB., GulerG.Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy.J BUON2013; 18: 366–71.
20.
KurebayashiJ., KanomataN., ShimoT.Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.Breast Cancer2014; 21: 214–22.
21.
ZenY., HeatonN.Elevated Ki-67 labeling index in ‘synchronous liver metastases’ of well differentiated enteropancreatic neuroendocrine tumor.Pathol Int2013; 63: 532–8.
22.
HajjajF.M., SalekM.S., BasraM.K.Non-clinical influences on clinical decision-making: a major challenge to evidence-based practice.J R Soc Med2010; 103: 178–87.
23.
ZhangJ.L., YaoQ., ChenY.W.J.H.Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer.Genet Mol Res2015; 14: 2099–103.
24.
SharmaS.Tumor markers in clinical practice: general principles and guidelines.Indian J Med Paediatr Oncol2009; 30: 1–8.
25.
LiuQ., WangX.Z., MuD.B.Correlation analysis of hormone receptors and the expressions of HER-2 and Ki-67 in breast cancer.Eur J Gynaecol Oncol2015; 36: 78–83.
